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Background:While non-alcoholic fatty liver disease (NAFLD) has been well characterised in patients with diabe-
tes mellitus (DM), less is known about NAFLD in non-DM patients. We investigated the clinical characteristics of
NAFLD patientswith andwithout DMand accuracy of theNAFLD ﬁbrosis score (NFS) in these twoNAFLD groups.
Methods: Clinical, biochemical and histological variables were evaluated in this prospective cross-sectional study
of 503 patients with biopsy proven NAFLD. Comparisons between patients with and without DMwere analysed.
NFS was correlated with liver histology to assess its robustness in patients with and without DM.
Results: There were 503 biopsy proven NAFLD patients with 48% of the cohort being diabetic. Relative to patients
withoutDM, patientswith DMwere older (52 vs. 46 years, p b 0.001), with higher proportion of females (70% vs.
54%, p b 0.001), higher BMI (37 vs. 35, p = 0.009), higher prevalence of hypertension (73% vs. 44%, p b 0.001),
higher prevalence of NASH (80.2% vs. 64.4%; p b 0.001) and advancedﬁbrosis (40.3% vs. 17.0%; p b 0.001). A con-
siderable amount of patients without DM still had NASH (64%) and advanced ﬁbrosis (17%). The clinical utility of
the NFS differed between NAFLD patients with and without DM, with sensitivity to exclude advanced ﬁbrosis
being 90% of NAFLD patients with DM but only 58% of patients without DM.
Conclusion: Patientswith DMhavemore severe NAFLD based onhistology. However, NASH and advancedﬁbrosis
also occur in a considerable proportion of NAFLD patients without DM. The lower utility of the NFS in NAFLD
patients without DM emphasises the heterogeneous nature of the NAFLD phenotype.© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).eaminotransferase;ALT,alanine
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Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation
of metabolic syndrome [1], represents a spectrum of histopathologic
abnormalities ranging from simple steatosis to the more aggressive
non-alcoholic steatohepatitis (NASH), characterised by steatosis, paren-
chymal inﬂammation, hepatocellular ballooning and other evidence of
hepatic injury [2]. Patients with NASH are at risk of developing progres-
sive ﬁbrosis; reported in up to 50% of cases over 6 years [3]. There is
increasing recognition that NAFLD is a heterogeneous diseasewithmul-
tiple pathways of pathogenesis and patients with different phenotypes
of NAFLD can presentwithdiverse diseasemanifestations [4]. Insulin re-
sistance plays a dominant role in thepathogenesis of NAFLD [5]. Patients
with type 2 diabetesmellitus (DM) have an increased risk of developing
NAFLD, NASH and hepatic ﬁbrosis/cirrhosis [6–9]. Furthermore, NAFLD
patients with DM have three times the mortality compared to non-C-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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reﬂected by its inclusion in the majority of the non-invasive composite
predictive scores for NASH and advanced ﬁbrosis [11–14]. One such
composite predictive score for predicting advanced ﬁbrosis in NAFLD
is the NAFLD ﬁbrosis score (NFS), which has been validated and recom-
mended for use in the American society guidelines [2,14]. Reiterating
disease heterogeneity and that NAFLD may not conform to a “one size
ﬁts all approach”, McPherson and colleagues had reported a difference
in the reliability of NFS in the context of normal and abnormal ALT
levels [15]. Other non-invasive ﬁbrosis scores such as the BARD score
and AST/ALT ratio have also been used to predict advanced ﬁbrosis in
NAFLD. We sought to characterise the clinical spectrum of NAFLD in
patients with and without DM. In addition, we explored the utility of
NFS and other established non-invasive ﬁbrosis scores among these
two groups.
2. Materials and methods
2.1. Study design and population
This is a prospective cross sectional study with patients enrolled
from two hepatology outpatient clinics in Cleveland, Ohio (Cleveland
Clinic and MetroHealth Medical Center). Study received approval from
the institutional review board.
The study included patients 18 years of age and over, with histolog-
ically provenNAFLD,whohad not received any prior therapies thatmay
have been beneﬁcial for NAFLD, such as Vitamin E, pentoxifylline,
pioglitazone and prescribed diet & exercise weight loss programmes.
Patients with excessive alcohol consumption (N21 drinks per week
and N14 drinks per week for males and females respectively) were
excluded. Similarly, patients with other contributory causes of liver
disease including those with hepatotoxic drug history, viral hepatitis,
hemochromatosis, autoimmune hepatitis, Wilson's disease or alpha 1
antitrypsin disease were excluded.
2.2. Ascertainment of clinical data
Demographic and clinical information was obtained by two of the
authors (SD or AM) for all patients from an electronic medical record
system that is common to both hospitals. The diagnosis of DM was
diagnosed based on American Diabetes Association (ADA) criteria
with or without the use of antidiabetic medications [16]. Hypertension
was diagnosed by the Joint National Committee (JNC) 7 criteria [17].
All diagnoses were veriﬁed based on documentation in the electronic
medical records by one of the investigators (SD or AM). Body mass
index (BMI) were collated, as were liver function tests [serum albumin,
bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase
(AST), alanine aminotransferase (ALT)], platelet count, international
normalised ratio (INR), total cholesterol (Chol), triglycerides (TGs),
high density lipoprotein (HDL) cholesterol, low density lipoprotein
(LDL) cholesterol, and HbA1C. To minimise inter-observer variability,
liver biopsy specimenswere readusing standardisedwell deﬁned histo-
logical criteria [18] established by the Non-alcoholic Steatohepatitis
Clinical Research Network (NASH CRN). As recommended, the diagno-
sis of NASH was based on the overall impression of histopathologists
and not the NAFLD activity score [NAS] [19]. Fibrosis was classiﬁed
into 4 stageswith advanced ﬁbrosis deﬁned as stage 3–4 ﬁbrosis (bridg-
ing ﬁbrosis–cirrhosis). Only clinical variables obtained within 6 months
of the liver biopsy were included in the analysis. The use of statins and
angiotensin-converting enzyme-inhibitor (ACE-I)/angiotensin receptor
blocker (ARB) within 6 months prior to the liver biopsy was also
examined. Insulin resistance was assessed with Homeostatic model
assessment—insulin resistance (HOMA-IR) based on the formula:
[fasting glucose (mg/dL) × insulin (μU/mL)] divided by 405 [20]. NFS
was calculated according to the published formula; NFS: −1.675 +
0.037 × age (years) + 0.094 × body mass index (BMI; kg/m2) +1.13 × impaired fasting glycaemia or DM (yes = 1, no = 0) + 0.99 ×
AST/ALT ratio − 0.013 × platelet (×109/L) − 0.66 × albumin (g/dL)
[14]. The cut-off points of the NFS used to categorise ﬁbrosis were:
b−1.455, −1.455 to 0.676, and N0.676 for low indeterminate and
high probability for advanced ﬁbrosis, respectively [14]. Calculation of
the BARD score was also performed; the BARD score was a 4 point
score derived from the weighted sum of three variables (BMI N 28 =
one point, AST/ALT ratio N 0.8 = two points, diabetes = one point)
where a score of two or more suggestive of advanced ﬁbrosis [13].
Similarly, AST/ALT ratio more than 0.8 itself has been suggested to be
useful in predicting advanced ﬁbrosis [21].
2.3. Statistical analysis
Descriptive statistics was computed for all variables and reported as
means and standard deviations (SDs) for continuous variables or fre-
quencies and percentages for categorical variables. Baseline characteris-
tics and differences in demographic, clinical, histological and laboratory
indices between patients with and without DMwere ascertained, using
Student's T tests and Pearson's chi-square testing for continuous and
categorical variables, respectively. Mann–Whitney U test was also
performed when applicable. The utility of NFS was correlated with his-
tological staging of ﬁbrosis in both DM and non-DM patients. With re-
gard to advanced ﬁbrosis, Spearman's correlation analysis for each
individual component of the NFS was performed in both patients with
and without DM. In addition, the utility of using ﬁbrosis scores such as
the BARD score and AST/ALT ratio was also assessed in both patients
with and without DM. All analyses were performed using SPSS version
21 statistical software (Chicago, Illinois, USA). Two sided p values
were used. p values b 0.05 were considered statistically signiﬁcant.
3. Results
Of the 503 NAFLD patients in the data set, 62%were female, 58% had
concomitant hypertension, 48% had concomitant DM and themean BMI
was 36.1 kg/m2. NASH and advanced ﬁbrosis were present in 71.8% and
28.1% of the cohort respectively.
Table 1 illustrates the characteristics of the whole cohort and also
patients with and without DM. Compared to NAFLD patients without
DM, patients with DM were older (52.5 vs. 46.0 years; p b 0.001),
were more likely to be female (70.7% vs. 54.0%; p b 0.001) and have a
higher BMI (37.2 vs. 35.2 kg/m2; p = 0.009). Diabetic patients were
also more likely to be hypertensive (73.2 vs. 43.9%; p b 0.001) with
greater use of statins (42.0 vs. 15.2%; p b 0.001) and ACE-I/ARBs (51.9
vs. 28.8%; p b 0.001). However, there was no difference in the preva-
lence of advanced ﬁbrosis among the DM patients taking or not taking
statins (p = 0.182) and also among the DM patients taking or not tak-
ing ACE-I/ARB (p = 0.357). There were differences in ALT, albumin,
platelet count, TG, LDL and HbA1C between the two groups. There was
no difference in aggregated length of liver tissue examined between pa-
tients with and without DM (19.9 mm vs. 18.2 mm; p = 0.225). As
shown in Table 2, patientswith diabetes hadmore lobular inﬂammation
(p= 0.017), ballooning (p b 0.001) and NASH (p b 0.001). The median
NAS was higher in DM patients compared to non-DM patients (p =
0.022). More of the DM patients had grade 2 ballooning (41.7% vs.
24.0%; p b 0.001) and higher prevalence of NASH (80.2% vs. 64.4%;
p b 0.001) compared to non-DM patients, while there was no differ-
ences in steatosis between patients with and without DM. DM patients
also had a higher prevalence of advanced ﬁbrosis (40.3% vs. 17.0%;
p b 0.001) [Table 1]. When cirrhosis was considered speciﬁcally, signif-
icantlymore of theDMpatients had cirrhosis relative to thenon-DMpa-
tients (20.6% vs. 5.7%) [Table 2]. Among theDMpatients, the duration of
DM did not differ between those with and without advanced ﬁbrosis
(5.79 vs. 5.42 years, p= 0.791). Similarly, HbA1C levels were compara-
ble between diabetic patients with and without advanced ﬁbrosis (7.5
vs. 7.3, p = 0.414). Among the patients without DM, there was no
Table 1
Characteristics of patients with NAFLD by the presence of DM status.
Characteristics Total
(n = 503)
Presence of DM p value⁎
Yes (n = 239) No (n = 264)
Age (years) 49 ± 12 52 ± 10 46 ± 12 b0.001
Proportion female (%) 311 (62.0) 169 (70.7) 142 (54.0) b0.001
BMI (kg/m2) 36.13 ± 8.43 37.16 ± 7.84 35.20 ± 8.84 0.009
Presence of HTN (%) 291 (57.9) 175 (73.2) 116 (43.9) b0.001
Bilirubin (mg/dL) 0.67 ± 0.39 0.68 ± 0.42 0.66 ± 0.37 0.648
AST (U/L) 56.15 ± 63.65 53.52 ± 36.03 58.52 ± 80.85 0.388
ALT (U/L) 71.70 ± 55.60 64.18 ± 49.21 78.49 ± 60.09 0.004
AST/ALT ratio 0.85 ± 0.37 0.92 ± 0.35 0.79 ± 0.37 b0.001
Albumin (g/dL) 4.25 ± 0.49 4.19 ± 0.53 4.30 ± 0.45 0.017
INR 1.03 ± 0.17 1.04 ± 0.18 1.02 ± 0.16 0.262
Platelet count (k/uL) 238.38 ± 77.68 230.85 ± 78.72 245.11 ± 76.27 0.045
Chol (mg/dL) 197.74 ± 50.87 192.99 ± 53.57 201.88 ± 48.13 0.068
TG (mg/dL) 206.7 ± 181.20 231.8 ± 223.50 184.7 ± 130.20 0.007
HDL (mg/dL) 42.86 ± 10.85 41.94 ± 10.72 43.69 ± 10.93 0.096
LDL (mg/dL) 122.11 ± 42.86 114.6 ± 44.77 128.75 ± 40.04 0.001
HbA1C (%) 6.58 ± 1.47 7.40 ± 1.51 5.62 ± 0.56 b0.001
Ferritin (ng/mL) 231.3 ± 230.90 209.1 ± 233.90 250.9 ± 227.00 0.076
Presence of NASH (%) 361 (71.8) 190 (80.2) 168 (64.4) b0.001
Presence of advanced
ﬁbrosis (%)
141 (28.1) 96 (40.3) 45 (17.0) b0.001
Length of specimen
(mm)
19.0 ± 10.8 19.9 ± 13.3 18.2 ± 8.0 0.225
Use of statin (%) 140 (27.9) 100 (42.0) 40 (15.2) b0.001
Use of ACE-I/ARBs (%) 200 (39.8) 124 (51.9) 76 (28.8) b0.001
Data are expressed as mean ± standard deviation or as number and percentage. BMI:
body mass index, HTN: hypertension, AST: aspartate aminotransferase, ALT: alanine ami-
notransferase, INR: international normalised ratio, Chol: total cholesterol, TG: triglyceride,
HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, ACE-I:
angiotensin-converting enzyme-inhibitor, ARB: angiotensin receptor blocker, DM:
diabetes mellitus.
⁎ p values were derived using Student's T tests and Pearson's chi-square tests on con-
tinuous and categorical variables respectively.
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sis (p= 0.732) [Table 3]. Table 4 represents the correlation of NFS to the
stage of ﬁbrosis. In thewhole cohort of patients, therewere 334 patients
without advanced ﬁbrosis on histology, of which 26 patients (7.8%)
werewrongly classiﬁed by the NFS. Hence, theNFSwas able to correctlyTable 2
Comparison of liver histology between DM and non-DM patients.
Histology feature Presence of DM p value⁎
Yes (n = 238) No (n = 263)
Grade of steatosis 0.500
0 5 (2.1%) 6 (2.3%)
1 85 (36.0%) 81 (30.9%)
2 79 (33.5%) 104 (39.7%)
3 67 (28.4%) 71 (27.1%)
Lobular inﬂammation 0.017
0 8 (3.4%) 28 (10.7%)
1 104 (44.1%) 113 (43.1%)
2 111 (47.0%) 109 (41.6%)
3 13 (5.5%) 12 (4.6%)
Ballooning b0.001
0 39 (16.6%) 70 (26.7%)
1 98 (41.7%) 129 (49.2%)
2 98 (41.7%) 63 (24.0%)
NAFLD activity score 0.200
NAS b 5 108 (46.0%) 136 (51.7%)
NAS ≥ 5 127 (54.0%) 127 (48.3%)
Median NAS (interquartile range) 5 (3) 4 (3) 0.022
Stage of ﬁbrosis b0.001
0 40 (16.8%) 98 (37.3%)
1 55 (23.1%) 79 (30.0%)
2 47 (19.7%) 41 (15.6%)
3 47 (19.7%) 30 (11.4%)
4 49 (20.6%) 15 (5.7%)
DM: diabetes mellitus, NAS: NAFLD activity score, NASH: non-alcoholic steatohepatitis.
⁎ p values were derived using Pearson's chi-square tests and Mann–Whitney U test.identify 92% of the patients as being without advanced ﬁbrosis. Of the
129 patients with advanced ﬁbrosis, 26 patients (20.2%) were wrongly
classiﬁed by the NFS. Analysing the utility of the NFS in subgroups strat-
iﬁed byDM, 14.4% (19/132) of DMpatientswithout advancedﬁbrosis as
opposed to 3.5% (7/202) of non-DM patients without advanced ﬁbrosis
were wrongly predicted as the high risk NFS category. Of the DM pa-
tients with advanced ﬁbrosis 10.1% (9/89) were inaccurately predicted
as the low risk NFS category, while 42.5% (17/40) of the non-DM pa-
tients with advanced ﬁbrosis were inaccurately predicted as the low
risk NFS category. Spearman's correlation analysis of the individual
components of NFS to advanced ﬁbrosis in both the patients with and
without DM was performed [Table 5]. This showed that in relation
to advanced ﬁbrosis, the correlation coefﬁcients of the individual
components used to calculate NFS were correspondingly lower in the
non-DM patients compared to the DM patients. Other ﬁbrosis scores
developed for NAFLD, namely the BARD score and AST to ALT ratio
were also tested in our cohort for their utility in patients with and
without DM [Table 6]. Similar to our ﬁndings with the NFS, there were
discrepancies in the utility of the BARD score and AST to ALT ratio
between patients with and without DM.
4. Discussion
The present study shows that the clinical spectrum of NAFLD is dif-
ferent among patients with and without DM. More aggressive NAFLD
as suggested by the higher prevalence of NASH and advanced ﬁbrosis
was seen in DM patients compared to non-DM patients. Other factors
contributing to more severe NAFLD in the DM patients include older
age, higher BMI and increased prevalence of hypertension. This is com-
patible with previous reports observing that patients with DM have
higher risk of NAFLD, higher rates of NASH and advanced ﬁbrosis rela-
tive to patients without DM [10,22,23]. In addition, DM is associated
with accelerated progression of hepatic ﬁbrosis [24], which is consistent
with the higher prevalence of cirrhosis among the DM patients relative
to the non-DM patients in our study. NAFLD patients with DM have
twice the mortality risk compared to the general population with DM
and no NAFLD [25]. Similarly, NAFLD patients with DM have three
times the overall mortality risk and twenty two times the liver related
mortality risk compared to NAFLD patients without DM [10]. In part,
this mortality risk relationship is contributed by DM patients having a
higher prevalence of NASH and advanced ﬁbrosis. Studies have ob-
served a higher overall mortality in patients with NASH relative to the
general population, in particular attributed to cardiovascular and liver
related mortality [26,27]. Comparing patients with and without NASH,
NASH was associated with higher rates of cirrhosis and liver-related
mortality [28]. This reiterates the importance of DM in the context of
NAFLD.
Liver biopsy remains the gold standard in diagnosing and predicting
the severity of NAFLD, with several histological features that can predict
clinically relevant outcomes in NAFLD [29]. With regard to liver histolo-
gy, our study found that inﬂammation and ballooning, integral features
required for the diagnosis of NASH, were more frequently seen among
NAFLD patients with DM, relative to patients without DM. Hepatocyte
injury in NAFLD is often noted in the form of hepatocellular ballooning,
and is often considered the most important histological feature
for distinguishing NASH [30,31]. Ballooning is associated with moreTable 3
Insulin resistance in relation to advanced ﬁbrosis in patients without DM.
HOMA-IR Advanced ﬁbrosis
Yes No
Tertile 1 7 (36.8%) 28 (43.8%) p = 0.732
Tertile 2 8 (42.1%) 27 (42.2%)
Tertile 3 4 (21.1%) 9 (14.1%)
HOMA-IR: Homeostatic model assessment—insulin resistance.
Table 4
Correlation of NFS and histology in patients with DM and without DM.
NFS DM Non-DM
Low risk Indeterminate High risk Total Low risk Indeterminate High risk Total
Stages 0–2 25 88 19 132 141 54 7 202
Stages 3–4 9 36 44 89 17 17 6 40
Total 34 124 63 158 71 13
Sensitivity 89.9% 49.4% 57.5% 15%
Speciﬁcity 18.9% 85.6% 69.8% 96.5%
PPV 42.8% 69.8% 27.4% 46.2%
NPV 73.5% 71.5% 89.2% 85.1%
NFS: NAFLD ﬁbrosis score, DM: diabetes mellitus, PPV: positive predictive value, NPV: negative predictive value.
Table 6
Correlation of BARD score and AST/ALT ratio to histology in patients with andwithout DM.
DM Non-DM
BARD b2 ≥2 Total BARD b2 ≥2 Total
144 G.B.-B. Goh et al. / BBA Clinical 3 (2015) 141–145aggressive NAFLD and higher rates of cirrhosis [28]. Similarly,
necroinﬂammation at index biopsy was reported to be the only predic-
tor of ﬁbrosis progression in an analysis of ten histo-pathological series
with follow-up liver biopsies [32].
The lower serum albumin and platelet count in combination with a
higher AST to ALT ratio seen with the DM patients reﬂect the higher
prevalence of advanced ﬁbrosis as they are recognised markers of
hepatic synthetic function, portal hypertension and surrogates of
advanced ﬁbrosis respectively [21,33].
Although DM has been proven to be an established risk factor for
NASH and advanced ﬁbrosis, the potential for severe disease in patients
without DM should not be overlooked. Several epidemiological studies
have reported prevalence rates of DM in NAFLD cohorts between 7
and 41% [1,8,14,34]. Consequently, although prevalence rates of NASH
and advanced ﬁbrosis may be lower among non-diabetics, taking into
account the larger number of patients in the non-diabetic group, the ab-
solute number of patients with signiﬁcantly severe NAFLD may not be
signiﬁcantly less than in diabetics. Indeed, in our study, a signiﬁcant pro-
portion of NAFLD patients without DM has NASH (64%) and advanced
ﬁbrosis (17%). This reiterates the need for cautious management of
NAFLD in the non-DM patient without trivialising the potential for dis-
ease severity in this subgroup of patients. Our study did not ﬁnd a signif-
icant association between severity of insulin resistance and advanced
ﬁbrosis among the patientswithout DM,whichmay suggest that factors
other than insulin resistance play amore prominent role in ﬁbrogenesis
among non-diabetics. This is consistent with the evolving recognition
that multiple factors (not just insulin resistance) are involved in the
pathogenesis of NAFLD [35,36].
With regard to non-invasive tools used in NAFLD, the NFS has been
widely used as a reliable tool to predict advanced ﬁbrosis in NAFLD
[14,37–39]. In our study, the NFS performed well in identifying patients
with and without advanced ﬁbrosis in the entire group. However sub-
group analysis suggested that the utility of the NFS had divergent clini-
cal reliability for NAFLD patients with and without DM, particularly in
excluding advanced ﬁbrosis in patients without DM although this
must be tampered in the context of a relatively lower prevalence of ad-
vanced ﬁbrosis among the non-DMpatients. Larger studies arewarrant-
ed to clarify the utility of the NFS in non-DM patients with NAFLD.
Nevertheless, this may illustrate the heterogeneous nature of the
NAFLD phenotype and that theNFSmay have to be adjusted in different
subsets of NAFLD patients. Similar discrepant ﬁndings using the BARD
score and AST/ALT ratios for predicting advanced ﬁbrosis between
patients with and without DM support the individualised approach toTable 5
Correlation of NFS components with advanced ﬁbrosis in patients with and without DM.
Advanced ﬁbrosis Age BMI Platelet Albumin AST/ALT
DM Rho 0.21 −0.72 −0.33 −0.18 0.36
p value 0.001 0.269 b0.001 0.007 b0.001
Non-DM Rho 0.20 0.05 −0.19 −0.14 0.31
p value 0.001 0.459 0.003 0.027 b0.001
NFS: NAFLD ﬁbrosis score, DM: diabetes mellitus, rho: correlation coefﬁcient, AST: aspar-
tate aminotransferase, ALT: alanine aminotransferase.this heterogeneous disease. A recent study observed differences in sen-
sitivity and speciﬁcity of NFS between NAFLD patients with andwithout
normal ALT levels; sensitivity of NFS (at lower cut-off) was good in pa-
tients with normal ALT at 82% but speciﬁcity was low at 51% [15].
Yoneda et al. had similar ﬁndings and suggested resetting the cut-off
values for NFS to achieve higher sensitivity and speciﬁcities in NAFLD
patients with normal ALT levels [40].
4.1. Strength and limitations
To our knowledge, this is the ﬁrst study to explore the clinical utility
of the commonly usedNFS inNAFLD patientswith andwithout DM. The
strength of this study include the large cohort of patients with histolog-
ically proven NAFLD in addition to the wide range of available demo-
graphic, anthropometric, clinical, histological and laboratory data.
However, there are a number of potential limitations. The cross-
sectional nature of our study allows the evaluation of associations
only. Furthermore, the use of electronic medical records to deﬁne the
presence or absence of DM and hypertension may have led to some
patients being misclassiﬁed. With regard to the NFS, the relatively
small number of patients with advanced ﬁbrosis in the non-diabetic
group may impact on the test performance of the NFS, in particular
the positive predictive value. Nevertheless, this study highlights impor-
tant clinical concepts which are relevant to the everyday practical
management of NAFLD.
5. Conclusion
While NAFLD patients with DM have higher prevalence of NASH
and advanced ﬁbrosis, the potential risk of severe NAFLD cannot be
overlooked in patients without DM since both NASH and advanced ﬁ-
brosis occur in a considerable proportion of these patients. The utility
of the NFS and other ﬁbrosis scores may have disparate clinical reliabil-
ity for NAFLD patients with and without DM, which emphasises the
heterogeneous nature of the NAFLD phenotype and that the NFS may
have to be adjusted in different subsets of NAFLDpatients. Thiswarrants
further studies to explore this relationship in greater detail.Stages 0–2 5 132 137 Stages 0–2 145 65 210
Stages 3–4 0 92 92 Stages 3–4 16 26 42
Total 5 224 229 Total 161 91 252
Sensitivity: 100%, speciﬁcity: 3.6%
PPV: 41.1%, NPV: 100%
Sensitivity: 61.9%, speciﬁcity: 69.0%
PPV: 28.6%, NPV: 90.0%
AST:ALT b0.8 ≥0.8 Total AST:ALT b0.8 ≥0.8 Total
Stages 0–2 78 59 137 Stages 0–2 146 65 211
Stages 3–4 21 71 92 Stages 3–4 16 26 42
Total 99 130 229 Total 162 91 253
Sensitivity: 77.2%, speciﬁcity: 56.9%
PPV: 54.6%, NPV: 78.8%
Sensitivity: 61.9%, speciﬁcity: 69.2%
PPV: 28.6%, NPV: 90.1%
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